Heat shock proteins and acute leukemias

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Heat shock proteins (HSPs) function as molecular chaperones, aiding protein refolding and degradation.
• HSPs influence apoptosis and are implicated in drug resistance in leukemia cells.
• High HSP expression is observed in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cells.

Purpose of the Study:

• To investigate the role of HSPs in leukemia cell survival and drug resistance.
• To explore the correlation between HSP expression levels and patient outcomes in leukemia.
• To evaluate HSPs as potential therapeutic targets in anticancer strategies.

Main Methods:

• Analysis of HSP expression levels in leukemia cells.
• Correlation studies between HSP expression and drug-induced apoptosis.
• Examination of HSP expression in relation to differentiation antigens and survival proteins.
• Review of clinical data including complete remission (CR) and overall survival (OS) rates.
• Assessment of HSP90 inhibitor 17-allylamino-17-demethoxygeldamycin (17-AAG) in phase I studies.

Main Results:

• Reduced HSP expression correlated with increased susceptibility to drug-induced apoptosis.
• HSP expression levels in AML and ALL cells were linked to drug resistance and apoptosis proteins.
• Lower HSP expression was associated with higher complete remission (CR) rates.
• Patients with lower HSP expression exhibited significantly longer overall survival (OS).
• Phase I studies of HSP90 inhibitor 17-AAG showed an acceptable toxicity profile and disruption of oncogenic proteins.

Conclusions:

• HSPs play a significant role in protecting leukemia cells from apoptosis and therapeutic agents.
• HSP expression levels serve as prognostic markers for CR and OS in leukemia patients.
• Targeting HSPs, particularly HSP90 with agents like 17-AAG, represents a promising therapeutic strategy in oncology.